The CUX1 Knockout AGS Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for the targeted disruption of the CUX1 gene in the human gastric adenocarcinoma cell line AGS. This loss-of-function model is generated via CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of cells harboring gene-inactivating lesions without clonal isolation. The product is supplied as a ready-to-use polyclonal knockout population, providing a practical tool for studying CUX1-dependent functions in a gastric cancer context while maintaining the genetic diversity inherent to polyclonal pools.
The AGS cell line, derived from a human gastric adenocarcinoma, serves as a widely employed epithelial model of gastric cancer. AGS cells retain key signaling pathway dependencies relevant to gastric carcinogenesis, including TGF-beta, Wnt, PI3K/AKT, and p53 pathways. Their well-characterized growth properties and responsiveness to external stimuli make them suitable for dissecting oncogenic mechanisms and screening therapeutic candidates. This host cell background, combined with CRISPR/Cas9-mediated CUX1 knockout, offers a physiologically relevant platform for investigating gene function within the gastric adenocarcinoma microenvironment.
CUX1 encodes a homeobox transcription factor that orchestrates cell cycle progression, differentiation, and DNA damage repair. CUX1 is activated by TGF-beta signaling and DNA damage cues, and is transcriptionally regulated by E2F factors. It directly interacts with p53, E2F1, HDAC1, and beta-catenin to modulate downstream targets such as CDKN1A (p21), CCND1 (cyclin D1), MYC, and invasion-related genes. CUX1 therefore integrates signals from TGFBR1?CSMAD2, CTNNB1 (beta-catenin), and PI3K/AKT pathways, influencing proliferation and genomic stability. Its dual role in promoting or repressing transcription depends on context, positioning it at the nexus of cell-cycle control and tumor suppression.
Disruption of CUX1 in AGS cells is expected to perturb cell-cycle regulation, attenuate DNA damage responses, and impair invasive potential, reflecting its multifaceted role in gastric cancer. Given the frequent dysregulation of TGF-beta, Wnt, and PI3K/AKT pathways in gastric adenocarcinomas, CUX1 knockout provides a tractable system to dissect how this transcription factor mediates oncogenic signaling and therapy resistance. The polyclonal knockout pool offers the advantage of capturing the full spectrum of functional consequences without clonal selection bias, enabling robust phenotypic profiling in a heterogeneous cancer cell population.
This CUX1 knockout model is suited for applications including gastric cancer mechanism studies, drug target validation, and functional genomics. Researchers can employ cell viability and colony formation assays to assess proliferation, wound healing and transwell assays for migration/invasion, and Western blotting or RT-qPCR to measure cell-cycle markers like p21 and cyclin D1. RNA-seq enables genome-wide transcriptomic analysis of CUX1-regulated networks, while drug sensitivity assays facilitate exploration of therapeutic vulnerabilities. For further technical specifications and ordering information, please contact Ascent Research.
